Dr. James (Jim) Woody, CEO of 180 Life Sciences Corp., a newly formed clinical-stage biotech company focused on novel drugs for unmet needs in inflammatory diseases, fibrosis, and pain, discusses three clinical programs using anti-TNF, with the lead program in Phase 2b/3 for Dupuytren’s contracture, a fibrotic disease of the hand. He previously led the team responsible for developing Remicade, the first of the TNF inhibitor biologics.
Dr. Gail McIntyre, CEO of Aravive, Inc., discusses the urgent need for improved therapeutic approaches to treat patients with ovarian cancer who are resistant to standard of care therapy and have limited treatment options. She explains the challenges with current treatment therapies and talks about Aravive’s lead product candidate, AVB-500, a unique and promising treatment approach for platinum resistant ovarian cancer.The company expects to initiate a pivotal trial during the first quarter of 2021.
Returning guest, Jon Friis, founder and CEO of MIIskin, the most popular consumer skin tracking platform in the world (500,000 users), and a partner of the Skin Cancer Foundation, discusses Miiskin Pro, the first telehealth solution (teledermatology) to streamline, for both the patient and the provider, the store-and-forward process of high-resolution images of the skin.
Returning guest, Dr. William Sandborn, MD, Chief of Gastroenterology, Professor of Medicine, University of California, San Diego, discusses positive study results in Crohn’s disease from the IM-UNITI trial on STELARA’S efficacy at five years and the TREMFYA GALAXI-1 trial, Phase 2, week 12 Interim Analyses Data. The GALAXI abstract has been recognized among the three highest scoring UEGW (United European Gastroenterology Week) 2020 abstracts in one of the main categories.
Dr. Diane Newman, urologic nurse practitioner from the University of Pennsylvania Penn Center for Continence and Pelvic Health, Division of Urology discusses overactive bladder, things that can be done to treat the condition and what medications are available.
November is Lung Cancer Awareness Month and Dr. Luis Raez, Chief Scientific Officer and Medical Director, Memorial Cancer Institute/Memorial Health Care System in Pembroke Pines, Florida, discusses a new blood test from Guardant Health that is the first FDA-approved comprehensive liquid biopsy. He talks about how it makes it easier to test lung cancer patients, and why comprehensive genomic profiling and biomarker testing is crucial for all cancer patients before starting treatment. He is joined by his patient Lynn Spadaccini who had learned she had stage 4 lung cancer and has benefitted from liquid biopsy and targeted treatment.
Returning guest, Dr. Gary Lelli, Associate Professor of Ophthalmology at Weill Cornell Medical College discusses the first annual Thyroid Eye Disease (TED) Awareness Week (Nov 16 – 20, 2020) that aimed to advocate for awareness and education for this serious, progressive and vision-threatening rare autoimmune disease, which in certain cases, can lead to blindness. Throughout the week, patients and caregivers were invited to tune into”TED Today”, a daily digital morning show hosted on the Listen To Your Eyes Facebook page featuring TED Specialists, patients and advocacy organizations to teach, inspire and create community among those living with or caring for someone tackling this rare disease. The five-episode series featured interviews from different TED perspectives, from patients and caregivers to ophthalmologists and mental health specialists.
Dr. Andrea Russo, MD, Director of Electrophysiology and Arrhythmia Services at Cooper University Hospital discusses the 50% decrease in in-person primary care visits, since COVID-19 according to a report from the IQVIA National Disease and Therapeutic Index. She talks about how this makes delays in the diagnosis of serious conditions like atrial fibrillation (AFib), deep vein thrombosis and pulmonary embolism and how important it is to get a proper diagnosis from a healthcare provider. There is a new campaign that seeks to bridge the gap in these critical diagnoses called “No Time To Wait“.
Dr. Irina Anselm, MD, Director of the Mitochondrial Program and Co-Director of the Neurometabolic Program at Boston Children’s Hospital discusses the ultra rare brain disorder of aromatic l-amino acid decarboxylase (AADC) deficiency, the symptoms, and disease burden. Patients with severe AADC deficiency have a high risk of death during childhood and there are currently no approved therapies that address the underlying cause. She talks about her work with families coping with AADC and the importance of the AADC Awareness Day, October 23, that shares resources to help families who face this devastating disease. Massachusetts will be the first state to sign a proclamation to officially declare this as an awareness day.
Dr. LeRoy Graham, MD, Founder and Medical Director of Not One More Life Asthma Care Program discusses a new project to address health disparities among people of color. The Not One More LifeTrusted Messengers project, a partnership among the Allergy & Asthma Network, Self Care Catalysts and global pharmaceutical company Sanofi, aims to address the factors that make the burden of COVID-19 unequal and empower Black Americans with the information and tools they need to take charge of their respiratory health, including a 16-week digital personalized intervention program for high-risk individuals.